SBX Corporation
SBX Corporation is a private Tokyo-based AI company that builds proprietary platforms (Garuda, Taxila, Gandhara) for AI-driven scientific discovery in biomedicine and drug discovery, serving enterprise pharmaceutical and cosmetics clients through co-development partnerships and consulting.
- Company typePrivate
- Founded2011
- HeadquartersHigashi-shinagawa, Japan
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What SBX Corporation does
SBX Corporation is a private Tokyo-based AI company founded on April 5, 2011, focused on building infrastructure for AI-driven scientific discovery in biomedicine and drug discovery. Its core technology stack consists of three proprietary platforms: Garuda Platform, which provides an open, community-driven framework for connecting and automating diverse biological data, devices, and analytics; Taxila Platform, an NLP/NLU-based text mining and intelligence engine for context-aware scientific literature analysis; and Gandhara AI Framework, an ensemble-learning system that integrates multiple machine learning and deep learning algorithms to deliver actionable and explainable insights in biomedicine. The company applies these platforms to drug discovery, clinical trials, healthcare, and adjacent domains.
SBX serves enterprise customers primarily through B2B co-development partnerships, joint research, and consulting engagements rather than standardized product sales. Named enterprise customers include POLA Chemical Industries (joint AIM POLAR R&D platform for cosmetics formulation) and Eisai (long-running AI mutagenicity prediction research). Revenue streams derive from R&D collaboration, custom software platform development and maintenance, and consulting services. The company operates through a group structure that includes the parent SBX Corporation (Tokyo), SBX Technologies Corporation (AI/ML, IoT, and model-based simulation), SBX BioSciences, Inc. (Vancouver, Canada, established 2020), and the affiliated non-profit Systems Biology Institute.
The company is led by President Hiroaki Kitano, Ph.D., a recognized pioneer in systems biology, supported by a team of Ph.D.-level scientists and engineers. With 11-50 employees and registered capital of JPY 5,000,000, SBX is a small, research-oriented firm that leverages academic publications, open-standards community participation (Garuda Alliance, SBML, SBGN, OpenTox), and conference engagement as core credibility and demand-generation channels, alongside direct enterprise relationships.
SBX Corporation firmographics
Firmographics- Name
- SBX Corporation
- Legal name
- SBX Corporation
- Website
- https://sbx-corp.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SBX Corporation is a private Tokyo-based AI company that builds proprietary platforms (Garuda, Taxila, Gandhara) for AI-driven scientific discovery in biomedicine and drug discovery, serving enterprise pharmaceutical and cosmetics clients through co-development partnerships and consulting.
- Ownership category
- akta.pro rank
SBX Corporation industry classification
Industry- Product category
- AI Drug Discovery Platforms
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Computer Systems Design and Related Services (54151), Custom Computer Programming Services (541511)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Computer Programming Services (7371), Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Pharmacovigilance & Drug Safety Software (HLAGAJAK), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Engineering & Model Development Services (BPAEAHAF)
Keywords
Where SBX Corporation is headquartered
LocationHeadquarters
- HQ city
- Higashi-shinagawa
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
SBX Corporation business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- R&D Collaboration and Joint Development: SBX engages in co-development partnerships with pharmaceutical and cosmetics companies, building custom AI platforms and solutions. Revenue derived from collaborative development projects, such as the AIM POLAR platform with POLA Chemical Industries and mutagenicity prediction systems with Eisai.
- Software Platform Development and Customization: Development, customization and maintenance of software platforms for drug discovery and life science research. Provides platforms (Garuda, Taxila, Gandhara) that can be customized for specific client needs.
- Consulting Services: Information provision and consulting on life science, drug discovery, and medical fields. R&D consulting and joint development services in drug discovery and personal genome areas.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
SBX Corporation product offering
Product offeringCore offering
SBX Corporation develops and customizes AI software platforms — Garuda Platform (connectivity and automation), Taxila Platform (NLP/NLU text mining) and Gandhara AI Framework (ensemble machine learning) — to support scientific discovery in drug discovery, toxicology, clinical research, healthcare and cosmetics R&D. The company also delivers bespoke AI solutions through co-development partnerships, such as the AIM POLAR R&D platform built with POLA Chemical Industries and AI mutagenicity prediction systems built with Eisai.
Product overview
SBX Corporation offers a platform-plus-modules architecture built around three core platforms: Garuda Platform for connectivity and automation, Taxila Platform for text-mining and analytics, and Gandhara AI Framework for machine learning and intelligence. These platforms serve as basic infrastructure for scientific discovery in drug discovery, clinical trials, and healthcare. The company also provides custom solutions including AIM POLAR (cosmetics R&D platform) and AI for sensory design, both developed with partner POLA Chemical Industries.
Differentiator
Problem solved
Functional benefit
Brands
- Garuda Platform: Open, community-driven platform providing framework to connect, discover and navigate through different applications, databases and services in biology and medicine. Also enables 'Powered by Garuda' framework for connectivity and automation.
- Taxila Platform
- Gandhara AI Framework
Products and services
- Garuda Platform Open, community-driven platform that provides a framework to connect, discover and navigate different applications, databases and services in biology and medicine, enabling connectivity and automation of diverse data, devices and analytics at scale. Built for life sciences, biomedical and healthcare R&D teams.
- Taxila Platform End-to-end analysis and intelligence platform combining NLP/NLU algorithms to analyze text in context, providing automatic context-aware aggregation and search of relevant scientific information via an AI-powered mining and analytics engine. Targeted at researchers and knowledge workers in drug discovery, life sciences and healthcare.
- Gandhara AI Framework Machine learning and intelligence framework providing an ensemble learning approach that integrates many ML and deep learning algorithms for big-data analytics focused on biomedicine and healthcare, delivering actionable and explainable insights. Used by SBX's research team and partners for predictive modeling tasks including mutagenicity prediction.
- AIM POLAR Revolutionary R&D platform for cosmetics jointly built with POLA Chemical Industries. Custom AI engines translate historical formulation data into precise predictions for product texture, safety and stability, with an intuitive touchpoint for researchers. For enterprise cosmetics R&D teams.
- AI for sensory design (触感づくりAI) AI tool that predicts sensory scores from cosmetic formulation information, enabling efficient and accurate in-silico prototyping for environmentally-friendly cosmetics development. For enterprise cosmetics R&D and product development teams.
- AI Mutagenicity Prediction System AI-based mutagenicity prediction system using machine-learning models trained on molecular structures, molecular properties and structural alerts to predict compound mutagenicity with high accuracy (AUC of 0.93 on the Hansen benchmark dataset). Developed with Eisai Co., Ltd. for use in drug discovery and toxicology risk assessment by pharmaceutical R&D teams.
Quantifiable outcome
- Mutagenicity prediction AUC of 0.93 on Hansen benchmark dataset
- +1 more outcomes
Companies that use SBX Corporation
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
SBX Corporation technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature5 records
SBX Corporation partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- POLA Chemical Industries Inc.coreSBX and POLA Chemical Industries jointly built the AIM POLAR R&D platform, a revolutionary system for cosmetics research. SBX was responsible for complete technical development, from the AI engine to user interface. POLA Chemical Industries provided deep industry knowledge and historical formulation data. This represents a true co-creation effort where SBX built custom AI engines to translate POLA's data into predictions for product texture, safety, and stability.
- Eisai Co., Ltd.coreLong-standing collaboration on AI mutagenicity prediction systems. Presented jointly at JSOT 2021 on 'Development of AI mutagenicity prediction system incorporating the knowledge of expert review'. Multiple co-authored publications including work on optimizing machine-learning models for mutagenicity prediction published in Mutagenesis journal.
- COVID-19 Disease Map ConsortiumcoreDr. Hiroaki Kitano of SBX participated in the global COVID-19 Disease Map initiative, co-authoring the paper 'COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms' in Scientific Data (Nature).
- The Systems Biology Institute (SBI)coreSBI is a non-profit private research institution established in 2000, affiliated with SBX Corporation. Focuses on promoting systems biology research and its application to medicine and global sustainability. Rapid translation of basic research to practical outcomes for business and clinical applications.
- SBX Technologies CorporationcoreProvides solutions to complex socio-industrial problems using AI/ML, IoT/sensor networks, and model-based simulation techniques. Part of the SBX Group ecosystem, solving problems pertinent to industrial and societal issues.
- SBX BioSciences, Inc.coreCanadian subsidiary established in 2020 in Vancouver. Provides professional services and end-to-end research solution building towards predictive biology, integrating AI and computational systems biology, and platform-empowered research by partnering with group entities.
- alumnus Software LtdminorEngineering partner listed on SBX website, providing software development and technical expertise.
- vikasietumminorEngineering partner listed on SBX website, providing technology consulting services.
- Infocomm Media Development Authority (IMDA) SingaporeminorIMDA hosted the Agentic AI in Healthcare seminar in Singapore on August 29, 2025, where SBX was a key presenter sharing insights from real-world experiences. Government agency promoting digital transformation in Singapore.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
SBX Corporation competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
SBX Corporation social profiles
Digital presenceSBX Corporation financial estimates
Financial estimateRevenue estimate
Valuation estimate
SBX Corporation leadership team
Management profileNumber of profiles
Profiles17 records
SBX Corporation subsidiaries and ownership
Company hierarchySubsidiaries3 records
SBX Corporation funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SBX Corporation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SBX Corporation
What does SBX Corporation do?
SBX Corporation develops and customizes AI software platforms — Garuda Platform (connectivity and automation), Taxila Platform (NLP/NLU text mining) and Gandhara AI Framework (ensemble machine learning) — to support scientific discovery in drug discovery, toxicology, clinical research, healthcare and cosmetics R&D. The company also delivers bespoke AI solutions through co-development partnerships, such as the AIM POLAR R&D platform built with POLA Chemical Industries and AI mutagenicity prediction systems built with Eisai.
Is SBX Corporation a public or private company?
SBX Corporation is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was SBX Corporation founded?
SBX Corporation was founded in 2011. It employs 11 to 50 people.
Where is SBX Corporation based?
SBX Corporation is headquartered in Higashi-shinagawa, Japan, in the Asia region.
How does SBX Corporation make money?
Three revenue lines are on record. R&D Collaboration and Joint Development is the primary driver. The others are software Platform Development and Customization and consulting Services.
Does SBX Corporation have an API?
No public API is recorded for SBX Corporation.
What industry is SBX Corporation in?
SBX Corporation's product category is AI Drug Discovery Platforms. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAK, Pharmacovigilance & Drug Safety Software. Its NAICS code is 541714 and its SIC code is 8731.